ABSTRACT
In this clinical study, the effect of serological status of rheumatoid arthritis (RA) on the possibility and timing of clinical remission while taking the main non-biological disease modifying anti-rheumatic drugs (DMARD) was analyzed. The relationship between presence and levels of antibodies to cyclic citrullinated peptide (ACCP) and/or rheumatoid factor (RF) and remission in RA has also been studied. It was found that the frequency of remission, including early one (during the first 6 months of treatment), is three times higher in ACCP negative patients with RA. The rate of remission (ratio of early to total remission) does not depend on the serological status: about two thirds of patients in all analyzed groups achieve remission in the first 6 months of DMARD therapy. ACCP and RF titers in the onset of the disease do not influence the possibility of remission achievement.
